Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat

Alkermes shares held near a 52-week high after the company said first-quarter 2026 earnings per share beat expectations, while the stock remained listed on Nasdaq in the United States.

Alkermes shares drew attention after the company reported first-quarter 2026 earnings per share of -$0.40, ahead of the -$0.54 consensus cited by Investing.com on 05/28/2026, while the stock was reported at a 52-week high of $39.57. The move keeps the Irish-domiciled biopharma group in focus on Nasdaq in the United States, where it trades under ALKS. According to a same-day report from Investing.com Australia, the stock also extended a recent momentum run that has drawn investor interest.

The stock traded at $39.57 on 05/28/2026 on Nasdaq, according to Investing.com Australia as of 05/28/2026. In the United States, Alkermes remains an active Nasdaq-listed name, and there is no dated allowed-source evidence of a completed delisting or take-private transaction.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ALKS
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Dublin, Ireland
• Core markets: United States, Europe
• Key revenue drivers: Commercial neuroscience and addiction therapies, plus collaborative and royalty income
• Home exchange/listing venue: Nasdaq (ALKS)
• Trading currency: USD

Alkermes plc: core business model

Alkermes develops and commercializes medicines in neuroscience and addiction, with revenue tied mainly to marketed products and partnered programs rather than a broad consumer-health portfolio.

Recent corporate actions

MarketBeat reported on 05/28/2026 that Fisher Asset Management increased its Alkermes position by 67,745 shares in the fourth quarter, a filing-based ownership update that adds a new same-day institutional angle to the stock. The filing did not indicate a change in listing status or any completed transaction affecting Alkermes' Nasdaq quotation.

Valuation metrics and multiples for Alkermes plc

Fresh valuation context is mixed but constructive after the price reached a 52-week high of $39.57 on 05/28/2026, while the same-day Investing.com item also highlighted the first-quarter 2026 EPS figure of -$0.40 versus the -$0.54 expectation. That combination suggests the market is paying close attention to earnings execution as well as share-price momentum, even though the available source set does not provide a full updated P/E or EV/EBITDA readout for the day.

For a home-country bridge, the main reference point remains Nasdaq in the United States, where Alkermes is still actively traded, and a German venue reference was not necessary for this session because the primary U.S. listing is fully verifiable.

Conclusion

Alkermes enters the latest session with a clear market catalyst in the form of a first-quarter 2026 earnings beat and a stock price that has reached a 52-week high. For Friday's valuation-focused lens, the key question is whether the current share price can be supported by further operating progress and additional disclosure from the company.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.